2022
Navigating barriers to affording and obtaining insulin and diabetes supplies
Wilcox A, Lipska K, Weinzimer S, Gujral J, Arakaki A, Kerandi L, Nally L. Navigating barriers to affording and obtaining insulin and diabetes supplies. Journal Of Diabetes 2022, 15: 71-75. PMID: 36562281, PMCID: PMC9870729, DOI: 10.1111/1753-0407.13344.Peer-Reviewed Original Research“It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes
Hughes A, Chapman K, Bispham J, Dimsits J, Weinzimer S, Wolf W, Heydarian N. “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes. Journal Of Clinical & Translational Endocrinology 2022, 30: 100310. PMID: 36620758, PMCID: PMC9816066, DOI: 10.1016/j.jcte.2022.100310.Peer-Reviewed Original ResearchSevere hypoglycemiaType 1 diabetesGlucagon useMini-dose glucagonEase of administrationPrescription costsNasal administrationEmergency treatmentGlucagon actionPerspectives of adultsHypoglycemiaDiabetesGlucagon treatmentHealthcare professionalsGlucagonAverage durationPerspectives of peopleAdministrationAdultsParticipantsFocus groupsTreatmentCurrent studyFocus group interviewsEmotional impactConsensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O’Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocrine Reviews 2022, 44: 254-280. PMID: 36066457, PMCID: PMC9985411, DOI: 10.1210/endrev/bnac022.Peer-Reviewed Original ResearchConceptsInsulin delivery technologiesGlycemic goalsNear-normal glucose levelsLong-term complicationsReal-world studyHypoglycemia riskDiabetes QualityConsensus recommendationsGlucose levelsGlobal prevalenceDiabetes managementEligibility criteriaClinical practiceDelivery technologiesHealthcare providersClinical settingDiabetesInsurance coverageSignificant proportionCliniciansAid successPWDPayersComplicationsTremendous advancesAssessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults
Commissariat PV, Volkening LK, Weinzimer SA, Dassau E, Laffel LM. Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults. Canadian Journal Of Diabetes 2022, 47: 66-72. PMID: 36184368, PMCID: PMC10096441, DOI: 10.1016/j.jcjd.2022.08.007.Peer-Reviewed Original ResearchConceptsYoung adultsTreatment surveyDiabetes device useLess diabetes distressCross-sectional studyType 1 diabetesQuality of lifeImpact of T1DInternal consistencyLower A1CMale sexDiabetes distressExcellent internal consistencyMedical recordsCGM useDiabetes managementT1DHealth outcomesDiabetesType 1Clinical interventionsPsychosocial outcomesBenefit findingA1CAdultsFeasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes
Deshpande S, Weinzimer SA, Gibbons K, Nally LM, Weyman K, Carria L, Zgorski M, Laffel LM, Doyle FJ, Dassau E. Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes. Journal Of Diabetes Science And Technology 2022, 18: 363-371. PMID: 35971681, PMCID: PMC10973844, DOI: 10.1177/19322968221116384.Peer-Reviewed Original ResearchType 1 diabetesUnannounced exercisePercent timeGlucose standard deviationParents/guardiansSecondary outcomesAdverse eventsPrimary outcomeBlood glucose dataPump therapyPreliminary safetyAutomated Insulin DeliveryContinuous glucose monitoring dataPediatric participantsGlucose monitoring dataAge-based cohortsArtificial pancreas systemsLarge mealsInsulin deliveryGlucose dataYoung childrenDiabetesYounger cohortsChildrenCohortLived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents
Hood KK, Garcia‐Willingham N, Hanes S, Tanenbaum ML, Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell F, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R, Consortium T. Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes Obesity And Metabolism 2022, 24: 2309-2318. PMID: 35837984, PMCID: PMC9804666, DOI: 10.1111/dom.14815.Peer-Reviewed Original Research1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 Diabetes
WILCOX A, MENCHER S, NALLY L, WEINZIMER S. 1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 Diabetes. Diabetes 2022, 71 DOI: 10.2337/db22-1025-p.Peer-Reviewed Original ResearchNon-Hispanic whitesDiabetes distressAdverse short-term outcomesBurden of diabetesShort-term outcomesType 1 diabetesHigher HbA1cContinuous glucose monitorElevated hemoglobinHigh prevalenceHigh riskDiabetesREM groupEthnic groupsEthnic disparitiesInsulin pumpAdolescent SurveyType 1Group of adolescentsRacial disparitiesSpeakers bureauDiabetes technologyNovo NordiskGlucose monitorAdditional mediatorsCambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial
Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell FM, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Hood KK, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R, Consortium D, Hovorka R, Acerini C, Thankamony A, Allen J, Boughton C, Dovc K, Dunger D, Ware J, Musolino G, Tauschmann M, Wilinska M, Hayes J, Hartnell S, Slegtenhorst S, Ruan Y, Haydock M, Mangat J, Denvir L, Kanthagnany S, Law J, Randell T, Sachdev P, Saxton M, Coupe A, Stafford S, Ball A, Keeton R, Cresswell R, Crate L, Cripps H, Fazackerley H, Looby L, Navarra H, Saddington C, Smith V, Verhoeven V, Bratt S, Khan N, Moyes L, Sandhu K, West C, Wadwa R, Alonso G, Forlenza G, Slover R, Towers L, Berget C, Coakley A, Escobar E, Jost E, Lange S, Messer L, Thivener K, Campbell F, Yong J, Metcalfe E, Allen M, Ambler S, Waheed S, Exall J, Tulip J, Buckingham B, Ekhlaspour L, Maahs D, Norlander L, Jacobson T, Twon M, Weir C, Leverenz B, Keller J, Davis N, Kumaran A, Trevelyan N, Dewar H, Price G, Crouch G, Ensom R, Haskell L, Lueddeke L, Mauras N, Benson M, Bird K, Englert K, Permuy J, Ponthieux K, Marrero-Hernandez J, DiMeglio L, Ismail H, Jolivette H, Sanchez J, Woerner S, Kirchner M, Mullen M, Tebbe M, Besser R, Basu S, London R, Makaya T, Ryan F, Megson C, Bowen-Morris J, Haest J, Law R, Stamford I, Ghatak A, Deakin M, Phelan K, Thornborough K, Shakeshaft J, Weinzimer S, Cengiz E, Sherr J, Van Name M, Weyman K, Carria L, Steffen A, Zgorski M, Sibayan J, Beck R, Borgman S, Davis J, Rusnak J, Hellman A, Cheng P, Kanapka L, Kollman C, McCarthy C, Chalasani S, Hood K, Hanes S, Viana J, Lanning M, Fox D, Arreaza-Rubin G, Eggerman T, Green N, Janicek R, Gabrielson D, Belle S, Castle J, Green J, Legault L, Willi S, Wysham C. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health 2022, 4: e245-e255. PMID: 35272971, DOI: 10.1016/s2589-7500(22)00020-6.Peer-Reviewed Original ResearchConceptsClosed-loop groupInsulin pump therapyType 1 diabetesControl groupBaseline HbAUsual carePump therapyClosed-loop insulin deliverySuboptimal glucose controlPediatric diabetes centersKey inclusion criteriaClosed-loop insulin delivery systemPrimary endpointBlock randomisationDiabetes CenterGlucose controlInsulin delivery systemsInclusion criteriaPrimary analysisTherapyInsulin deliveryMonthsG pumpHbADiabetes
2021
Youth and parent preferences for an ideal AP system: It is all about reducing burden
Commissariat PV, Roethke LC, Finnegan JL, Guo Z, Volkening LK, Butler DA, Dassau E, Weinzimer SA, Laffel LM. Youth and parent preferences for an ideal AP system: It is all about reducing burden. Pediatric Diabetes 2021, 22: 1063-1070. PMID: 34324772, PMCID: PMC8530854, DOI: 10.1111/pedi.13252.Peer-Reviewed Original ResearchPredictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System
Schoelwer MJ, Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cobry EC, Messer LH, Cengiz E, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, Buckingham BA, Lal RA, Oliveri MC, Kollman CC, Dokken BB, Cherñavvsky DR, Beck RW, DeBoer MD, Gonder-Frederick L, Robic J, Voelmle M, Conschafter K, Morris K, Barnett C, Carr K, Hellmann J, Kime M, Todd Alonso G, Slover R, Berget C, Towers L, Lange S, Buckingham B, Maahs D, Lal R, Ekhlaspour L, Norlander L, Hood K, Town M, Weir C, Smith K, Hsu L, Shinksy D, Viana J, Cengiz E, Weinzimer S, Weyman K, Carria L, Zgorski M, Ruedy K, Beck R, Borgman S, Rusnak J, Kanapka L, Kollman C, Murphy C, Arreza-Rubin G, Green N, Kovatchev B, Brown S, Anderson S, Breton M, Laffel L, Pinsker J, Levy C, Kudva Y, Wadwa R, Buckingham B, Doyle III F, Renard E, Cobelli C, Reznik Y, Arreza-Rubin G, Lum J, Beck R, Ruedy K, Janicek R, Gabrielson D. Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technology & Therapeutics 2021, 23: 475-481. PMID: 33689454, PMCID: PMC8252894, DOI: 10.1089/dia.2020.0646.Peer-Reviewed Original ResearchConceptsGlycemic controlLower TIROptimal glycemic controlType 1 diabetesPredictors of timeGreater improvementClinical characteristicsClinical predictorsFourth quartileMore insulinBody weightGlucose monitor dataExtension phaseMultivariate modelBolusStrongest predictorContinuous glucose monitor dataQuartileInsulinPredictorsChildrenParticipantsT1D.T1DDiabetesImpact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study.
Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, Reiss AL. Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. Diabetes Care 2021, 44: 983-992. PMID: 33568403, PMCID: PMC7985430, DOI: 10.2337/dc20-2125.Peer-Reviewed Original ResearchConceptsType 1 diabetesBrain volumeControl subjectsTotal brain volume differencesEarly-onset type 1 diabetesAge-matched control subjectsIntelligence quotientCognitive scoresWhite matter volumeBrain volume differencesContinuous glucose monitoringDiabetes groupFull-scale intelligence quotientDiabetes complicationsDiabetes controlTotal brainVerbal intelligence quotientDiabetesMatter volumeSensor glucoseCognitive testingGlucose monitoringMixed-effects modelsBrainGroup differencesExtended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes.
Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer MJ, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, DeBoer MD, Buckingham BA, Oliveri M, Kollman C, Dokken BB, Cherñavvsky D, Beck RW. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. Diabetes Care 2021, 44: 473-478. PMID: 33355258, PMCID: PMC7818334, DOI: 10.2337/dc20-1729.Peer-Reviewed Original ResearchConceptsType 1 diabetesChildren 6Sensor-augmented pump therapyWeeks of useDiabetic ketoacidosisDays of useGlycemic controlSAP groupSevere hypoglycemiaPump therapyClinical trialsPercentage of timeCLC groupMean TIRDiabetesFurther evaluationCohortRCTsDlWeeksChildrenDaysExtended useParticipantsKetoacidosis
2020
Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes
Nimri R, Battelino T, Laffel LM, Slover RH, Schatz D, Weinzimer SA, Dovc K, Danne T, Phillip M. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nature Medicine 2020, 26: 1380-1384. PMID: 32908282, DOI: 10.1038/s41591-020-1045-7.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin dose adjustmentPhysician armDose adjustmentAcademic diabetes centerInsulin pump settingsPrimary efficacy measureSevere adverse eventsTarget glucose rangeInsulin pump therapyNon-inferiority trialArtificial intelligence-based decision support systemAdverse eventsInsulin titrationDiabetes CenterEfficacy measuresPump therapyPercentage of timePercentage of readingsGlucose levelsSix monthsContinuous glucose monitoring devicesDiabetesInsulin pumpGlucose monitoring devicesA Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. New England Journal Of Medicine 2020, 383: 836-845. PMID: 32846062, PMCID: PMC7920146, DOI: 10.1056/nejmoa2004736.Peer-Reviewed Original ResearchConceptsType 1 diabetesSensor-augmented insulin pumpClosed-loop groupGlucose levelsMedian percentageTarget rangeInsulin pumpInsulin deliveryParallel-group trialYears of ageContinuous glucose monitoringDiabetic ketoacidosisPrimary outcomeSevere hypoglycemiaHemoglobin levelsRandomized trialsGlycemic outcomesPercentage of timeChildren 6Control groupType 1DiabetesMean percentageGlucose monitoringTrials998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and Parents
ROETHKE L, COMMISSARIAT P, FINNEGAN J, VOLKENING L, BUTLER D, DASSAU E, WEINZIMER S, LAFFEL L. 998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and Parents. Diabetes 2020, 69 DOI: 10.2337/db20-998-p.Peer-Reviewed Original ResearchDiabetes careT1D durationInsulin pumpType 1 diabetesBoehringer Ingelheim PharmaceuticalsSanofi USDiabetes CenterDifferent treatment situationsSpouse/partnerInsulin delivery systemsCare burdenGlucose levelsJanssen PharmaceuticalsT1DArtificial pancreas systemsDiabetesEmotional burdenParents of youthYoung adultsSpeakers bureauCareAge 10Emotional distressNational InstituteUnderwent content analysisBrain Function Differences in Children With Type 1 Diabetes: A Functional MRI Study of Working Memory
Foland-Ross LC, Tong G, Mauras N, Cato A, Aye T, Tansey M, White NH, Weinzimer SA, Englert K, Shen H, Mazaika PK, Reiss AL, Tsalikian E, Tansey M, Coffey J, Cabbage J, Salamat S, Bisbee R, Mauras N, Fox L, Cato A, Englert K, Sikes K, Ewen T, Bird K, Buckingham B, Wilson D, Aye T, Kingman R, Weinzimer S, Tamborlane W, Ambrosino J, Steffen A, Weyman K, Zgorski M, White N, Arbelaez A, Levandoski L, Starnes A, Hershey T, Reiss A, Foland-Ross L, Marzelli M, Mazaika P, Tong G, Sperling M, Becker D, Cleary P, Greenbaum C, Moran A. Brain Function Differences in Children With Type 1 Diabetes: A Functional MRI Study of Working Memory. Diabetes 2020, 69: 1770-1778. PMID: 32471809, PMCID: PMC7372069, DOI: 10.2337/db20-0123.Peer-Reviewed Original ResearchConceptsType 1 diabetesImproved glycemic controlBrain function differencesFunctional MRI studyGreater modulationDiabetes groupGlycemic controlFrontoparietal cortexMRI studiesControl groupDiabetesType 1Functional MRICompensatory mechanismsEarly onsetBrain activationVisuospatial Working Memory TaskChildrenN-back taskMemory functionEarly ageMemory abilityWorking Memory TaskFuture studiesActivationPrecision Dosing of Rapid-Acting Insulin Matters
Aanstoot HJ, Rodriguez H, Weinzimer S, Vint N, Koeneman L. Precision Dosing of Rapid-Acting Insulin Matters. Diabetes Technology & Therapeutics 2020, 22: 346-351. PMID: 32125891, DOI: 10.1089/dia.2019.0374.Peer-Reviewed Original ResearchConceptsGood glycemic controlGlycemic controlHalf-unit insulin pensInsulin pensDiabetes managementInsulin deliveryStringent glycemic controlInadequate glycemic controlType 2 diabetesType 1 diabetesPrecision of dosingDelivery devicesInsulin delivery devicesInsulin therapyGeriatric patientsHypoglycemic eventsPatient preferencesFlexible dosingPhysical activityDosingLiterature searchPrecision dosingDiabetesInsulinCorrective doses
2019
816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D)
COMMISSARIAT P, ROETHKE L, VOLKENING L, BUTLER D, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D). Diabetes 2019, 68 DOI: 10.2337/db19-816-p.Peer-Reviewed Original ResearchDiabetes careBurden of T1DSelf-care burdenDiabetes technologyType 1 diabetesEli LillyArtificial pancreasUnderwent thematic analysisT1D durationNovo Nordisk A/SCarbohydrate countingSpouse/partnerCare burdenSemi-structured qualitative interviewsT1D careJanssen PharmaceuticalsMedtronic MiniMedPatients' hopeAP uptakeHeart rate monitorT1DDiabetesYoung adultsSpeakers bureauCare817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) Survey
COMMISSARIAT P, VOLKENING L, ROETHKE L, GUO Z, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) Survey. Diabetes 2019, 68 DOI: 10.2337/db19-817-p.Peer-Reviewed Original ResearchDiabetes careYoung personLess diabetes distressType 1 diabetesEli LillyInternal consistencyAdvanced diabetes technologiesMale sexDiabetes distressNovo Nordisk A/SSpouse/partnerGood internal consistencyT1D careDiabetesJanssen PharmaceuticalsMedtronic MiniMedMultidisciplinary teamTreatment surveySignificant associationPsychosocial outcomesYouth ages 8T1DCeiling effectsTotal scoreIllness identity
2018
Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial
Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, Ekhlaspour L, Church MM, Weinzimer SA, Jost E, Marcal T, Andre C, Carria L, Swanson V, Lum JW, Kollman C, Woodall W, Beck RW. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care 2018, 41: dc180771. PMID: 30089663, DOI: 10.2337/dc18-0771.Peer-Reviewed Original ResearchConceptsType 1 diabetesSAP armPredictive low glucose suspendSensor-augmented pump therapyNew insulin delivery systemsRandomized Crossover StudySevere hypoglycemic eventsGlucose concentrationMin/dayMean glucose concentrationLow glucose suspendBasal-IQRebound hyperglycemiaSlim X2Glycemic controlPrimary outcomeCrossover studyMedian timeCrossover trialHypoglycemic eventsPump therapyInsulin delivery systemsPercentage of timeHypoglycemiaDiabetes